



ASX Announcement

20th December 2023

Resignation of Non-Executive Director

SYDNEY, Australia, December 20, 2023 - Atomo Diagnostics Limited (ASX:AT1) (**Atomo** or the **Company**) advises that at 5.52pm (AEDT) on 19 December 2023, Dr Curt LaBelle has notified the Board of his resignation as a director of the Company with immediate effect.

Dr LaBelle was appointed to the Board as a Non-Executive Director on 21 October 2016.

Atomo's Chair, John Keith, commented on the resignation: "On behalf of the Board, I warmly thank Curt for his valuable contribution to Atomo. Curt leaves our Board with the very best wishes."

For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by John Keith, Non-Executive Chair, and John Kelly, Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com